Intuitive Surgical, Inc. $ISRG Shares Sold by Phoenix Financial Ltd.

Phoenix Financial Ltd. decreased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 16.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,892 shares of the medical equipment provider’s stock after selling 2,623 shares during the quarter. Phoenix Financial Ltd.’s holdings in Intuitive Surgical were worth $7,305,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in Intuitive Surgical by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock worth $15,026,776,000 after acquiring an additional 263,828 shares during the last quarter. Capital World Investors grew its stake in Intuitive Surgical by 1.5% during the 3rd quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock valued at $3,456,223,000 after acquiring an additional 116,034 shares in the last quarter. Fisher Asset Management LLC grew its stake in Intuitive Surgical by 1.1% during the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock valued at $1,739,475,000 after acquiring an additional 40,702 shares in the last quarter. Amundi grew its stake in Intuitive Surgical by 29.7% during the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after acquiring an additional 739,444 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in Intuitive Surgical by 11.1% during the 4th quarter. Jennison Associates LLC now owns 3,209,137 shares of the medical equipment provider’s stock valued at $1,817,527,000 after acquiring an additional 321,759 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $428.06 on Friday. The firm has a market capitalization of $151.60 billion, a price-to-earnings ratio of 51.89, a PEG ratio of 3.45 and a beta of 1.51. The company’s 50-day moving average is $465.23 and its two-hundred day moving average is $514.69. Intuitive Surgical, Inc. has a 1-year low of $417.74 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. Intuitive Surgical’s revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.81 EPS. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 500 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $473.46, for a total value of $236,730.00. Following the transaction, the director directly owned 239 shares in the company, valued at $113,156.94. The trade was a 67.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Myriam Curet sold 105 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total transaction of $51,864.75. The SEC filing for this sale provides additional information. Insiders sold a total of 5,647 shares of company stock worth $2,760,359 over the last ninety days. 0.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on ISRG shares. JPMorgan Chase & Co. dropped their price objective on shares of Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. BTIG Research reaffirmed a “buy” rating and set a $574.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, April 22nd. Robert W. Baird upped their price objective on shares of Intuitive Surgical from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Zacks Research cut shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Piper Sandler dropped their price objective on shares of Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Eighteen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $581.91.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.